Liraglutide Tied to Significant Weight Loss in Obese

Share this content:
Liraglutide Tied to Significant Weight Loss in Obese
Liraglutide Tied to Significant Weight Loss in Obese

MONDAY, Oct. 2, 2017 (HealthDay News) -- Liraglutide significantly increases weight loss in obese patients, likely by slowing gastric emptying of solids, according to a pilot study published online Sept. 25 in The Lancet Gastroenterology & Hepatology.

Houssam Halawi, M.D., from the Mayo Clinic in Rochester, Minnesota , and colleagues compared the effects of liraglutide and placebo over 16 weeks on gastric motor functions, satiation, satiety, and weight in obese patients (BMI ≥30 kg/m2). Seventeen patients were randomized to the liraglutide group and 18 to the placebo group, and all patients received standardized nutritional and behavioral counseling. Both liraglutide and placebo were increased by 0.6 mg per day each week for five weeks and continued until week 16.

The researchers found that compared with placebo, liraglutide retarded gastric emptying of solids at five (P < 0.0001) and 16 (P = 0.025) weeks, caused significant weight loss at five weeks (P < 0.001) and 16 weeks (P < 0.001), and increased satiation, as measured by lowered maximum tolerated volume, at 16 weeks (P = 0.05) versus the placebo group. From five to 16 weeks of treatment there was tachyphylaxis to the gastric emptying effects of liraglutide. In the treatment group, nausea was the most common adverse event.

"Measurement of gastric emptying (e.g. at 5 weeks of treatment) may be a biomarker of responsiveness and may help select patients for prolonged treatment with this class of medication," conclude the authors.

Some trial medication supplies were supplied by Novo Nordisk.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Characteristics of Severe Hypoglycemia Identified in T2DM

Characteristics of Severe Hypoglycemia Identified in T2DM

Increased odds of severe hypoglycemia with history of non-severe hypoglycemia, HbA1c <6 percent

Hand-Holding, Stress Ball Don't Cut Anxiety in Skin CA Removal

Hand-Holding, Stress Ball Don't Cut Anxiety in Skin ...

No incremental anxiety reduction versus control in patients during excisional skin cancer surgery

L-Glutamine Reduces Number of Pain Crises in Sickle Cell Disease

<small>L</small>-Glutamine Reduces Number of Pain Crises in Sickle ...

Significantly fewer pain crises, hospitalizations compared with those receiving placebo

is free, fast, and customized just for you!




Already a member?

Sign In Now »